TDC
CRL icon

Thompson Davis & Co’s Charles River Laboratories CRL Stock Holding History

Thompson Davis & Co’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-183
Closed -$20K – 761
2017
Q3 		$20K Sell
183
-17
-9% -$1.75K 0.04% 479
2017
Q2 		$20K Buy
+200
New +$18.4K 0.03% 459

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Thompson Davis & Co's CRL Position: Q4 2017 in Review

Thompson Davis & Co sold out of Charles River Laboratories (CRL) in Q4 2017, closing a stake of 183 shares — an estimated $20K sold.

Thompson Davis & Co first reported a position in CRL in Q2 2017 and held it in 2 quarters. The position peaked at $20K in Q3 2017. 339 funds tracked by Wall St. Rank hold CRL as of Q4 2017.

  • Thompson Davis & Co reported no remaining Charles River Laboratories position as of Q4 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 183 Charles River Laboratories shares in Q4 2017, an estimated $20K.
  • Thompson Davis & Co first reported a position in Charles River Laboratories in Q2 2017 and held it in 2 quarters.
  • Thompson Davis & Co's Charles River Laboratories position peaked at $20K in Q3 2017.
  • 339 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2017.

Based on Thompson Davis & Co's 13F filing for Q4 2017, filed 5 Feb 2018.